JP2023531090A5 - - Google Patents
Info
- Publication number
- JP2023531090A5 JP2023531090A5 JP2022580273A JP2022580273A JP2023531090A5 JP 2023531090 A5 JP2023531090 A5 JP 2023531090A5 JP 2022580273 A JP2022580273 A JP 2022580273A JP 2022580273 A JP2022580273 A JP 2022580273A JP 2023531090 A5 JP2023531090 A5 JP 2023531090A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- region containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010620778.8 | 2020-06-30 | ||
| CN202010619083 | 2020-06-30 | ||
| CN202010619111.6 | 2020-06-30 | ||
| CN202010619111 | 2020-06-30 | ||
| CN202010619083.8 | 2020-06-30 | ||
| CN202010620778 | 2020-06-30 | ||
| PCT/CN2021/103687 WO2022002153A1 (zh) | 2020-06-30 | 2021-06-30 | 用于治疗肿瘤的药物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531090A JP2023531090A (ja) | 2023-07-20 |
| JP2023531090A5 true JP2023531090A5 (https=) | 2024-07-09 |
| JP7799638B2 JP7799638B2 (ja) | 2026-01-21 |
Family
ID=79317451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580273A Active JP7799638B2 (ja) | 2020-06-30 | 2021-06-30 | 腫瘍を治療するための薬物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230310596A1 (https=) |
| EP (1) | EP4174087A4 (https=) |
| JP (1) | JP7799638B2 (https=) |
| CN (1) | CN115698076A (https=) |
| AU (1) | AU2021301947A1 (https=) |
| CA (1) | CA3188017A1 (https=) |
| WO (1) | WO2022002153A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3227992A1 (en) * | 2021-08-05 | 2023-02-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition for treating small cell lung cancer |
| WO2023232100A1 (zh) * | 2022-06-02 | 2023-12-07 | 正大天晴药业集团股份有限公司 | 用于治疗子宫恶性肿瘤的药物组合 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102476226B1 (ko) * | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| US9751859B2 (en) * | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| CN116769054A (zh) * | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| CN107460221B (zh) * | 2016-06-02 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法 |
| CN110573172A (zh) * | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| KR102642385B1 (ko) * | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| US20210147547A1 (en) * | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CN113861295B (zh) * | 2018-07-20 | 2024-05-24 | 厦门大学 | 抗pd-1抗体及其用途 |
| JP7582952B2 (ja) * | 2019-01-25 | 2024-11-13 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 腫瘍治療用の併用医薬組成物 |
| CN119424632A (zh) * | 2019-07-03 | 2025-02-14 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗结直肠癌的联用药物组合物 |
-
2021
- 2021-06-30 JP JP2022580273A patent/JP7799638B2/ja active Active
- 2021-06-30 EP EP21833511.5A patent/EP4174087A4/en active Pending
- 2021-06-30 CN CN202180041400.5A patent/CN115698076A/zh active Pending
- 2021-06-30 WO PCT/CN2021/103687 patent/WO2022002153A1/zh not_active Ceased
- 2021-06-30 AU AU2021301947A patent/AU2021301947A1/en active Pending
- 2021-06-30 CA CA3188017A patent/CA3188017A1/en active Pending
- 2021-06-30 US US18/003,718 patent/US20230310596A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2019517549A5 (https=) | ||
| RU2019133787A (ru) | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования | |
| JP2021511372A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023531090A5 (https=) | ||
| JP2023510199A5 (https=) | ||
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| CN113018429A (zh) | 治疗卵巢癌的药物组合 | |
| JP2021518348A5 (https=) | ||
| JP2024527974A5 (https=) | ||
| CN116209443A (zh) | 治疗小细胞肺癌的药物组合 | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| CN115698076A (zh) | 用于治疗肿瘤的药物 | |
| JP2023500480A5 (https=) | ||
| JP2022530599A5 (https=) | ||
| JP2022549218A5 (https=) | ||
| CN120752053A (zh) | 含抗tim-3抗体的药物组合 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| WO2024051670A1 (zh) | 结合tim-3的抗体与结合pd-1的抗体的药物组合 | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 |